Day 2 | Friday, August 30

15:45-16:17 Poster Session 1: Biomarkers / Cell Biology and Translational Research

- **P-001** MicroRNA-148a-5p Inhibits CD44 Expression and Epithelial-Mesenchymal Transitions in Hepatocellular Carcinoma Cells
  - Si Hyun Bae (Korea)

- **P-002** METFORMIN CONTRIBUTES TO COLLAGEN TYPE 1 PRODUCTION IN LIVER CANCER OF T2-DIABETIC RAT
  - Wahyuni Lukita Atmodjo (Indonesia)

- **P-003** Association Of Genetic Variants Of ATP-Binding Cassette B5 (ABCB5) And Hepatocellular Carcinoma Risk
  - Charing CN CHONG (Hong Kong)

- **P-004** Relationship between Change in α-fetoprotein (AFP) and Patient Survival in Hepatocellular Carcinoma (HCC): a Real-world Electronic Medical Records Database Study
  - Yoshinori Tanizawa (Japan)

15:45-16:09 Poster Session 2: Biomarkers / Cell Biology and Translational Research

- **P-004** Exosome derived circular non-coding RNA panel as biomarkers for early diagnosis of hepatocellular patient
  - JUNG WOO EUN (Korea)

- **P-005** Molecular characteristics Associated with 18F-FDG Uptake in Intrahepatic Cholangiocarcinoma
  - Koo Jeong Kang (Korea)

- **P-006** Tumor-stroma crosstalk enhances REG3A expressions that drive the progression of hepatocellular carcinoma
  - Yuri Cho (Korea)

15:45-16:33 Poster Session 3: Viral Hepatitis / Cirrhosis and Related Complications

- **P-007** Hepatocellular Carcinoma in Patients with Non-cirrhotic Liver at Mandalay General Hospital, Myanmar
  - Moe Z Maung (Myanmar)

- **P-008** Stage of Hepatocellular Carcinoma at the Time of Diagnosis in Mandalay General Hospital, Myanmar
  - Sithu Lin (Myanmar)

- **P-009** The risk of hepatocellular carcinoma in cirrhosis combined with OGTT confirmed diabetes
  - Moon Young Kim (Korea)

- **P-010** Changing trends in epidemiology and clinical outcomes of Korean patients with liver cirrhosis: An eight-year single center experience
  - Sunmin Kim (Korea)

- **P-011** Comparing Clinical Patterns of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease and Hepatitis B
  - Benjamin Wei Rong Tay (Singapore)

- **P-012** Impact of On-Treatment Intermediate Endpoints on the Risk of Hepatocellular Carcinoma in HBeAg-Positive Chronic Hepatitis B Patients
  - Young-Suk Lim (Korea)

15:45-16:25 Poster Session 4: Diagnosis and Liver Imaging / Epidemiology and Surveillance / Miscellaneous

- **P-013** Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease
  - Won Kim (Korea)

- **P-014** Incidence of hepatocellular carcinoma development in cirrhotic patients has not been decreased during past 10 years; A single center experience.
  - Jeong Han Kim (Korea)
### Poster Session 5: Molecular Pathogenesis and Pathology / Staging and Prognosis

**P-018** Clinical manifestation and survival outcomes according to body mass index in hepatocellular carcinoma patients; an analysis of a nationwide cancer registry database
- **Jung Hwan Yu** (Korea)

**P-019** The Relationship between Spleen Size and Prognosis in Patients Receiving Transarterial chemoembolization (TACE) for Hepatocellular carcinoma (HCC)
- **Byung Ik Kim** (Korea)

**P-020** Portal hypertension and muscle volume loss in early HCC patients with Child-Pugh A, who are treated curatively
- **Atsushi Hiraoka** (Japan)

**P-021** Clinical features and risk factors for extrahepatic metastasis of hepatocellular carcinoma after radiofrequency ablation: A retrospective study of 662 patients in two tertiary hospitals
- **Jae Hyun Yoon** (Korea)

**P-022** Relationship between Hepatitis C Virus and Activated Interferon Signaling in Hepatocellular Carcinoma from TCGA data
- **Yoshinari Asaoka** (Japan)

### Poster Session 6: Treatment: Systemic, Targeted, Novel Target or Experimental Therapy

**P-023** Impacts of diabetes and hypertension on hepatocellular carcinoma patients receiving sorafenib
- **Jung-Ta Kao** (Taiwan)

**P-024** The Real-World Practice of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma in Taiwan
- **Yen-Hao Chen** (Taiwan)

**P-025** The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma which beyond REFLECT study indications in a real-world setting
- **Gong Li** (China)

**P-026** Which is the first choice for the treatment of advanced HCC, lenvatinib or sorafenib?
- **Takuya Adachi** (Japan)

**P-027** Effectiveness of Dose Reduction of Sorafenib on HCC Treatment: A real life multicenter data analysis
- **Jeong Won Jang** (Korea)

### Poster Session 7: Treatment: Systemic, Targeted, Novel Target or Experimental Therapy

**P-028** Anti-Tumor Effect of Ginsenoside Rh2 and Rg5 in Xenograft Hepatoma Animal Model - Comparison with Sorafenib
- **Jae Young Jang** (Korea)

**P-029** Genomic and clinical significance of the thioredoxin system and TXNDC family in hepatocellular carcinoma
- **Hyuk Soo Eun** (Korea)

**P-030** Cytochrome P450 4A11 expression in hepatocellular carcinoma cells
- **Hyuk Soo Eun** (Korea)

**P-031** Comprehensive analysis of cytochrome P450 family 4 gene expression in hepatocellular carcinoma
- **Hyuk Soo Eun** (Korea)

**P-101** Hand Foot Skin Reaction (HFSR) Predicts Better Outcomes in HCC Treated with Sorafenib: Analysis of Hong Kong Real-life Cohort
- **Thomas Yau** (Hong Kong)
### Poster Session 8: Treatment: Surgical Resection and Transplantation

**P-032** Factors and Models for Predicting Liver-related Morbidity in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma  
_Jonggi Choi (Korea)_

**P-033** Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation and/or transcatheter arterial chemoembolization: A propensity score-matched analysis.  
_Tatsuya Orimo (Japan)_

**P-034** The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma  
_Sunyoung Lee (Korea)_

**P-035** Assessment of recurrence factor for treated hepatocellular carcinoma by using intraoperative radiofrequency ablation  
_Hyuk Soo Eun (Korea)_

**P-036** Albumin bilirubin (ALBI) score as a predictive value of post hepatectomy liver failure comparable to ICG R15 in HCC.  
_Hyun Joon Park (Korea)_

### Poster Session 9: Treatment: Surgical Resection and Transplantation

**P-037** Prognosis of patients with advanced hepatocellular carcinoma underwent by surgical resection after sorafenib resistance (Report of 14 cases)  
_Liqun Wu (China)_

**P-038** A case of primary hepatic mucosa-associated lymphoid tissue lymphoma developed from the normal liver  
_Takeshi Aiyama (Japan)_

**P-039** Long term survival after multiple resections and radiofrequency ablation for metachronous development of hepatocellular carcinoma following intrahepatic cholangiocarcinoma in a single patient  
_Masahiro Hagiwara (Japan)_

**P-040** ASYMPTOMATIC LATE HEPATIC ARTERY THROMBOSIS AFTER LIVING DONOR LIVER TRANSPLANTATION: A CASE REPORT  
_Thanh V. Le (Vietnam)_

**P-041** A combined resection of vena cava and associated reconstruction using cryo-preserved venous allograft in hepatic resection for intrahepatic cholangiocarcinoma  
_Junichi Arita (Japan)_

**P-042** A resected case of fibrolamellar hepatocellular carcinoma which recurred 2 years after the primary operation  
_Kyung Hwa Park (Japan)_

### Poster Session 10: Treatment: Transarterial Approach / Percutaneous Ablative Therapy / Radiation Therapy

**P-043** Efficacy and Safety of Percutaneous Radiofrequency Ablation in Treatment of Small Hepatocellular Carcinoma in Myanmar (Single Centre Study)  
_A Mi Mi Kyaw (Myanmar)_

**P-044** Second Line Treatment for Recurrent Hepatocellular Carcinoma after Curative Treatment - Single Center Experience-  
_Soung Won Jeong (Korea)_

**P-045** Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2cm or smaller: a 10-year experience of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation in Taiwan  
_Ching-Sheng Hsu (Taiwan)_

**P-046** Current status of therapeutic choice and feasibility for hepatocellular carcinoma patients over 70 years old  
_Hyun Woong Lee (Korea)_

**P-047** BCLC-B Subclassifications Associate with Tumor Response and Liver Decompensation to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma  
_Chen-Ta Chi (Taiwan)_
<table>
<thead>
<tr>
<th>15:45-16:33</th>
<th><strong>Poster Session 11 : Treatment: Transarterial Approach / Percutaneous Ablative Therapy / Radiation Therapy</strong></th>
</tr>
</thead>
</table>
| **P-048**   | Clinical Outcomes of Stereotactic Body Radiation Therapy for Single Viable Hepatocellular Carcinoma at the Site of Incomplete Transarterial Chemoembolization  
Jinhong Jung (Korea) |
| **P-049**   | A new prognosis prediction model in patients with hepatocellular carcinoma after Yttrium-90 radioembolization  
Jae Seung Lee (Korea) |
| **P-050**   | Platelet-to-Lymphocyte Ratio Prior to Transarterial Radioembolization for Hepatocellular Carcinoma is More Predictive of Disease Response than Neutrophil-to-Lymphocyte Ratio  
Kliment K Bozhilov (USA) |
| **P-051**   | Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy  
Wen-Yen Huang (Taiwan) |
| **P-052**   | Does the necessity of more sessions of downstaging treatment of hepatocellular carcinoma prior to liver transplantation pose a higher potential of postoperative recurrence?  
Kuo-Shyang Jeng (Taiwan) |
| **P-053**   | Multicenter Phase II Study of Stereotactic ABlative Radiotherapy for Hepatocellular Carcinoma within the Milan Criteria (KROG 12-02)  
WON IL JANG (Korea) |
### Day 3 | Saturday, August 31

**Poster (Royton Hall Foyer), 3F**

#### 13:45-14:09  
**Poster Session 12: Biomarkers / Cell Biology and Translational Research**

- **P-054** Limited Bias Effect Of Intratumoral Heterogeneity On Genetic Profiling Of Hepatocellular Carcinoma  
  Ao Huang (China)

- **P-055** Predictive value of peripheral blood immune profiling in advanced hepatocellular carcinoma.  
  Yi-Ping Hung (Taiwan)

- **P-056** CD38 predicts response to immune checkpoint inhibitors in hepatocellular carcinoma (HCC)  
  David Tai (Singapore)

#### 13:45-14:09  
**Poster Session 13: Viral Hepatitis / Cirrhosis and Related Complications**

- **P-057** Tenofovir and Entecavir has Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization  
  Young Youn Cho (Korea)

- **P-058** Real State of Antiviral Therapy in the Patient with Hepatitis C Related Hepatocellular Carcinoma  
  Hyun Young Woo (Korea)

- **P-059** Cumulative Incidence of Hepatocellular Carcinoma and Hepatitis B Surface Antigen Seroclearance After Nucleos(t)ide analogue induced Hepatitis B e Antigen Seroclearance  
  Hyun Woong Lee (Korea)

#### 13:45-14:17  
**Poster Session 14: Diagnosis and Liver Imaging / Epidemiology and Surveillance / Miscellaneous**

- **P-060** Targetoid Mass on Gadoxetic Acid-enhanced MRI Using LI-RADS v2018: Emphasis on Hepatocellular Carcinomas Assigned to the LR-M Category  
  Hyun Jeong Park (Korea)

- **P-061** Inter-reader Agreement of the LI-RADS for the Diagnosis of Hepatocellular Carcinoma on MRI: A Systematic Review and Meta-analysis  
  Ji Hun Kang (Korea)

- **P-062** Associations between tumor gene expression, fluorocholine PET/CT imaging phenotype, and post-resection survival in early-stage hepatocellular carcinoma.  
  Sandi A. Kwee (USA)

- **P-063** Change in the Recurrence Pattern and Risk Factors over Time after the Complete Cure of Hepatocellular Carcinoma: Ten-Year Follow-Up Study  
  Han Ah Lee (Korea)

#### 13:45-14:25  
**Poster Session 15: Diagnosis and Liver Imaging / Epidemiology and Surveillance / Miscellaneous**

- **P-064** Potential Etiology, Prevalence of Cirrhosis, and Mode of Detection among Patients with Non-B Non-C Hepatocellular Carcinoma in Korea  
  Jihye Kim (Korea)

- **P-065** The Impact of HBsAg and HBeAb on Noninvasive Diagnostic Criteria for Hepatitis B Virus-related Hepatocellular Carcinoma  
  Bei Tang (China)

- **P-066** A significant diagnostic role for discrimination of malignancy of Contrast enhanced ultrasound for portal vein thrombosis in HCC patients  
  Jung Hyun Kwon (Korea)

- **P-067** Role of Contrast Enhanced Ultrasound in Surveillance for Hepatocellular Carcinoma: a Pictorial Review  
  Carmen Cho (Hong Kong)

- **P-068** The Clinical Behavior and Survival of Patients with Hepatocellular Carcinoma and a Family History of the Disease  
  Ju Hyun Shim (Korea)
<table>
<thead>
<tr>
<th>13:45-14:09</th>
<th><strong>Poster Session 16 : Molecular Pathogenesis and Pathology / Staging and Prognosis</strong></th>
<th>Ryosuke Tateishi (Japan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-069</td>
<td>A Case of Transitional Liver Cell Tumor in a 10-Year-Old Boy</td>
<td>Momoko Ara (Japan)</td>
</tr>
<tr>
<td>P-070</td>
<td>LncRNA CCAT2 Genetic Polymorphisms are Associated with Susceptibility to Hepatocellular Carcinoma</td>
<td>Kuan-Chun Hsueh (Taiwan)</td>
</tr>
<tr>
<td>P-071</td>
<td>A case of fibrolamellar hepatocellular carcinoma successfully treated with surgical resection</td>
<td>Seong Kyun Na (Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13:45-14:25</th>
<th><strong>Poster Session 17 : Treatment: Systemic, Targeted, Novel Target or Experimental Therapy</strong></th>
<th>Masayuki Kurosaki (Japan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-072</td>
<td>Efficacy and Safety of Nivolumab after Failure of Sorafenib for Advanced Hepatocellular Carcinoma (HCC): A Prospective Cohort Study</td>
<td>KyungHye Bang (Korea)</td>
</tr>
<tr>
<td>P-073</td>
<td>Factors associated with Post-progression Survival in Advanced Hepatocellular Carcinoma Patients with Post-sorafenib Progression not eligible for Regorafenib</td>
<td>Chang Wook Kim (Korea)</td>
</tr>
<tr>
<td>P-074</td>
<td>Unnecessity of preoperative transarterial chemoembolization in patients with resectable hepatocellular carcinoma</td>
<td>Ho Joong Choi (Korea)</td>
</tr>
<tr>
<td>P-075</td>
<td>Magnetic hyperthermia effect of chitosan-bilirubin coated nanoparticle in the treatment of hepatocellular carcinoma</td>
<td>Yong Yeon Jeong (Korea)</td>
</tr>
<tr>
<td>P-076</td>
<td>Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-flurouracil versus sorafenib for hepatocellular carcinoma with failure of transarterial chemoembolization using doxorubicin</td>
<td>Sunhong Yoo (Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13:45-14:09</th>
<th><strong>Poster Session 18 : Treatment: Clinical Trials</strong></th>
<th>Ken Shirabe (Japan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-100</td>
<td>Implementation of an Enhanced Recovery After Surgery Program in Patients Undergoing hepatectomy for Primary Liver Cancer</td>
<td>Rongfa Yuan (China)</td>
</tr>
<tr>
<td>P-077</td>
<td>A phase 3 study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab in patients with locoregional HCC: EMERALD-1</td>
<td>Masatoshi Kudo (Japan)</td>
</tr>
<tr>
<td>P-078</td>
<td>Durvalumab With or Without Bevacizumab as Adjuvant Therapy for Patients at High Risk of Recurrence After Curative Therapy: EMERALD-2</td>
<td>Norihito Kokudo (Japan)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13:45-14:41</th>
<th><strong>Poster Session 19 : Treatment: Surgical Resection and Transplantation</strong></th>
<th>Toshiya Kamiyama (Japan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-079</td>
<td>Improved outcomes of laparoscopic liver resection for hepatocellular carcinoma located in posterosuperior segments of the liver</td>
<td>Jai Young Cho (Korea)</td>
</tr>
<tr>
<td>P-080</td>
<td>The safety and efficacy of liver surgery for very elderly patients.</td>
<td>Tomoki Hakozaki (Japan)</td>
</tr>
<tr>
<td>P-081</td>
<td>Long-term survival of laparoscopic hepatectomy for hepatocellular carcinoma: A single-center experience</td>
<td>Akihisa Nagatsu (Japan)</td>
</tr>
<tr>
<td>P-082</td>
<td>Failure to Achieve sequential Hepatectomy for Hepatocellular Carcinoma after Preoperative Portal Vein Embolization</td>
<td>Yosuke Nakao (Japan)</td>
</tr>
<tr>
<td>P-083</td>
<td>Comparison of single port laparoscopic and open surgery in minor hepatectomy for hepatocellular carcinoma.</td>
<td>Tae Yun Lee (Korea)</td>
</tr>
<tr>
<td>P-084</td>
<td>Simulation of remnant liver ischemia by three-dimensional visualization technology based on pre-operative CT scan</td>
<td>Xiao-Long Li (China)</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>---------</td>
</tr>
<tr>
<td>P-085</td>
<td>Is laparoscopic hepatectomy suitable for giant hepatic hemangioma larger than 10 cm in diameter?</td>
<td>Bin Jin (China)</td>
</tr>
<tr>
<td>P-086</td>
<td>Appraisal of Transarterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma</td>
<td>Jonggi Choi (Korea)</td>
</tr>
<tr>
<td>P-087</td>
<td>Prognostic value of alpha-fetoprotein in patients who achieved complete response to transarterial chemoembolization for hepatocellular carcinoma</td>
<td>Jae Seung Lee (Korea)</td>
</tr>
<tr>
<td>P-088</td>
<td>Prognostic value of des-γ-carboxy prothrombin responses in recurrent hepatocellular carcinoma patients treated with transarterial chemoembolization</td>
<td>Yi Chen (China)</td>
</tr>
<tr>
<td>P-089</td>
<td>Albumin-Bilirubin (ALBI) and Platelet-Albumin-Bilirubin (PALBI) Grade for Predicting of Three Months Survival in HCC Patients Receiving Transarterial Chemoembolization</td>
<td>Ummi Maominah (Indonesia)</td>
</tr>
<tr>
<td>P-090</td>
<td>Strengthening intraoperative hemodynamic monitoring for nursing patients with liver rupture of liver cancer</td>
<td>YiLing Cao (China)</td>
</tr>
<tr>
<td>P-091</td>
<td>Survival Comparison of Patients with Hepatocellular Carcinoma undergoing Single vs. high-risk re - Transarterial Chemoembolization: which one is better?</td>
<td>Poernomo B Setiawan (Indonesia)</td>
</tr>
<tr>
<td>P-092</td>
<td>Conventional TACE could be Ineffective for Tumor Necrosis in patients of HCC with Micro-Vascular Invasion (MVI); MVI Could be a Strong Indicator for Recurrence within 2-year after Curative Hepatic Resection.</td>
<td>JOON HO JEONG (Korea)</td>
</tr>
<tr>
<td>P-093</td>
<td>Aortocele angle in percutaneous implantation of port-catheter system for hepatic arterial infusion chemotherapy: comparison of subclavian VS femoral approach</td>
<td>Ho Jong Chun (Korea)</td>
</tr>
<tr>
<td>P-094</td>
<td>Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma</td>
<td>Hwa Kyung Byun (Korea)</td>
</tr>
<tr>
<td>P-095</td>
<td>Phase II Clinical Trial of Stereotactic Body Radiation Therapy for Small (≦ 5 cm) Hepatocellular Carcinoma not Amenable to Curative Treatment</td>
<td>Sang Min Yoon (Korea)</td>
</tr>
<tr>
<td>P-096</td>
<td>Prognostic Performance of Inflammation-based Prognostic Scores in Patients with Hepatocellular Carcinoma Treated with Stereotactic Ablative Radiotherapy</td>
<td>Cheng-Hsiang Lo (Taiwan)</td>
</tr>
<tr>
<td>P-097</td>
<td>Treatment Response of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis to Radiation Therapy Utilizing Helical Tomotherapy HDA</td>
<td>Michael Martin H Malabanan (Philippines)</td>
</tr>
<tr>
<td>P-098</td>
<td>The safety of stereotactic body radiotherapy using helical tomotherapy for hepatocellular carcinoma in terms of intermediate dose spillage</td>
<td>Sun Hyun Bae (Korea)</td>
</tr>
</tbody>
</table>